Drug General Information
Drug ID
D00JED
Former ID
DIB013295
Drug Name
AN-2898
Synonyms
PDE4 inhibitor (topical, psoriasis/atopic dermatitis), Anacor
Indication Atopic dermatitis [ICD9: 691.8, 692.9; ICD10:L00-L99] Phase 2 [523369]
Company
Anacor Pharmaceuticals Inc
Structure
Download
2D MOL

3D MOL

Canonical SMILES
c1(c(cc(cc1)Oc1cc2c(cc1)B(OC2)O)C#N)C#N
Target and Pathway
Target(s) Type IV phosphodiesterase Target Info Inhibitor [532329]
CAMP-specific 3',5'-cyclic phosphodiesterase 4B Target Info Inhibitor [532329]
CAMP-specific 3',5'-cyclic phosphodiesterase 4A Target Info Inhibitor [532329]
KEGG Pathway Purine metabolism
cAMP signaling pathway
Morphine addictionhsa00230:Purine metabolism
Morphine addiction
NetPath Pathway IL5 Signaling Pathway
IL2 Signaling Pathway
PathWhiz Pathway Purine Metabolism
Reactome DARPP-32 events
G alpha (s) signalling eventsR-HSA-180024:DARPP-32 events
G alpha (s) signalling events
WikiPathways G Protein Signaling Pathways
Myometrial Relaxation and Contraction Pathways
TSH signaling pathwayWP35:G Protein Signaling Pathways
Nuclear Receptors Meta-Pathway
Opioid SignallingWP35:G Protein Signaling Pathways
References
Ref 523369ClinicalTrials.gov (NCT01301508) Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis. U.S. National Institutes of Health.
Ref 532329An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.